The stock of Enfusion Inc (ENFN) has seen a -0.58% decrease in the past week, with a -0.22% drop in the past month, and a 4.18% flourish in the past quarter. The volatility ratio for the week is 0.90%, and the volatility levels for the past 30 days are at 1.56% for ENFN. The simple moving average for the past 20 days is -1.53% for ENFN’s stock, with a 15.75% simple moving average for the past 200 days.
Is It Worth Investing in Enfusion Inc (NYSE: ENFN) Right Now?
The price-to-earnings ratio for Enfusion Inc (NYSE: ENFN) is above average at 543.87x. The 36-month beta value for ENFN is also noteworthy at 0.93. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENFN is 48.88M, and at present, short sellers hold a 1.94% of that float. The average trading volume of ENFN on March 19, 2025 was 1.05M shares.
ENFN) stock’s latest price update
The stock price of Enfusion Inc (NYSE: ENFN) has jumped by 0.05 compared to previous close of 11.09. Despite this, the company has seen a fall of -0.58% in its stock price over the last five trading days. zacks.com reported 2025-03-03 that Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.
Analysts’ Opinion of ENFN
Many brokerage firms have already submitted their reports for ENFN stocks, with Morgan Stanley repeating the rating for ENFN by listing it as a “Overweight.” The predicted price for ENFN in the upcoming period, according to Morgan Stanley is $11 based on the research report published on May 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ENFN reach a price target of $8, previously predicting the price at $9. The rating they have provided for ENFN stocks is “Sell” according to the report published on February 28th, 2024.
JP Morgan gave a rating of “Underweight” to ENFN, setting the target price at $9 in the report published on January 30th of the previous year.
ENFN Trading at 0.08% from the 50-Day Moving Average
After a stumble in the market that brought ENFN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.97% of loss for the given period.
Volatility was left at 1.56%, however, over the last 30 days, the volatility rate increased by 0.90%, as shares surge +0.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.28% upper at present.
During the last 5 trading sessions, ENFN fell by -0.49%, which changed the moving average for the period of 200-days by +18.39% in comparison to the 20-day moving average, which settled at $11.27. In addition, Enfusion Inc saw 7.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENFN starting from Bastone Bronwen, who sale 3,126 shares at the price of $11.38 back on Mar 05 ’25. After this action, Bastone Bronwen now owns 221,875 shares of Enfusion Inc, valued at $35,558 using the latest closing price.
Campobasso Matthew, the General Counsel of Enfusion Inc, sale 1,695 shares at $11.38 during a trade that took place back on Mar 05 ’25, which means that Campobasso Matthew is holding 70,946 shares at $19,281 based on the most recent closing price.
Stock Fundamentals for ENFN
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.68 for the gross margin
The net margin for Enfusion Inc stands at 0.01. The total capital return value is set at 0.05. Equity return is now at value 4.45, with 2.24 for asset returns.
Based on Enfusion Inc (ENFN), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 1.71.
Currently, EBITDA for the company is 6.16 million with net debt to EBITDA at -2.35. When we switch over and look at the enterprise to sales, we see a ratio of 5.05. The receivables turnover for the company is 6.3for trailing twelve months and the total asset turnover is 1.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.
Conclusion
In summary, Enfusion Inc (ENFN) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
